Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
| Autor: | Yasameen Abbas, Nabaa Ihsan, Asal Adnan, Marwa Moayad, Ali AlKazzaz, Avin Maroof, Ali Abdulrahman, Nazar Abdulateef, Mohammad AlOsami, Faiq Gorial, Mohammed Altahhan, Zahraa Almansi, Ali Alnoori |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | مجله كليه طب الكندي, Vol 20, Iss 3 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1810-9543 2521-4365 |
| DOI: | 10.47723/2km3dk27 |
| Popis: | Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods: A Cross sectional Observational study Started on 69 RA Records receiving Amgevita. Data collected from local registry then examined for disease activity and adverse reactions for 9 months follow up. Results: Thirty patients completed the 9 months period of the study: aged (49±14) years; 77.5% females. After 3, 6 and 9 months of follow up, patients' mean (SD) CDAI 27.8 ( 13.60 ) which was statistically lower (19.80) (6.96), 17.70 (2.790), and 19 (1.040), p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|